What are the side effects of Voranigo (Vorasidenib)?

Voranigo (Vorasidenib) is a targeted therapy for certain types of brain tumors, primarily used to treat grade 2 astrocytoma or oligodendroglioma in patients aged 12 years and older. These patients usually have isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutations and have undergone surgical treatment, including biopsy, subtotal resection, or total resection. Although Voranigo significantly improved the prognosis of these patients, its side effects cannot be ignored.

In Voranigo’s clinical trials, a series of side effects were observed. The most common adverse reactions with an incidence rate of 15% or more include fatigue, headache, COVID-19, musculoskeletal pain, diarrhea, nausea and epileptic seizures. These side effects may affect a patient's quality of life and cause them to feel uncomfortable during treatment. For example, fatigue is a symptom frequently reported by patients and may affect their daily activities and overall mental state. In addition, headaches and musculoskeletal pain may also require adjustments to daily life and work schedules.

In addition to the above common adverse reactions, some laboratory test results show that the incidence of grade 3 or 4 side effects related to Voranigo is low (≥2%), but it still requires attention. These laboratory abnormalities mainly include elevated alanine aminotransferase (ALT), elevated aspartate aminotransferase (AST), elevated gamma-glutamyl transferase (GGT), and neutropenia. Elevations in these indicators often indicate impaired liver function or increased risk of infection, and may require appropriate monitoring and management. During treatment, your doctor may perform regular blood tests to detect and treat these potential problems.